← Back to patent-cliff list

CAS 32981-86-5

(2alpha,5beta,7beta,10beta,13alpha)-4-(Acetyloxy)-1,7,10,13-tetrahydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-acetoxy-4,6,9,11-tetrahydroxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxet-12-yl benzoate

Codes: (XIII)101438-2-a, (I)101438-8-a, (XI)101438-21-a, (I)101438-33-a, (I)101438-43-a, (VI)101438-47-a, (I)101438-52-a, (I)101438-58-a, (I)101438-77-a, (I)140605-5-a, (I)140605-6-a, (I)140605-12-a +9 more

Application context (from source-drug indications)

Breast cancerPaclitaxel/Encequidar mesylateAdenocarcinomaPaclitaxel/Encequidar mesylateAngiosarcomaPaclitaxel/Encequidar mesylateSolid tumourPaclitaxel/Encequidar mesylateBladder cancerDocetaxel polymeric micelle (Samyang Biopharmaceuticals)Head and neck cancerDocetaxel polymeric micelle (Samyang Biopharmaceuticals)Head and neck squamous cell carcinomaDocetaxel polymeric micelle (Samyang Biopharmaceuticals)Solid tumourDocetaxel polymeric micelle (Samyang Biopharmaceuticals)Pancreatic cancerPaclitaxelNon-small cell lung cancerPaclitaxelHodgkin's diseasePaclitaxelSeminomaPaclitaxelOvarian cancerPaclitaxelBreast cancerPaclitaxelNon-small cell lung cancerDocetaxel (Beihai)Prostate cancerDocetaxel (Beihai)Castration-resistant prostate cancerDocetaxel (Beihai)Breast cancerDocetaxel (Beihai)Head and neck cancerDocetaxel (Beihai)Head and neck squamous cell carcinomaDocetaxel (Beihai)Prostate cancerCabazitaxelAdenocarcinomaCabazitaxel食管胃结合部肿瘤CabazitaxelGastric cancerCabazitaxel生殖细胞和胚胎肿瘤Cabazitaxel睾丸肿瘤Cabazitaxel

Source drugs (routes using this intermediate)

DrugTierExpiry
Paclitaxel/Encequidar mesylateTier C — Watch / trade-
Docetaxel polymeric micelle (Samyang Biopharmaceuticals)Tier C — Watch / trade-
PaclitaxelTier B — Position early-
Docetaxel (Beihai)Tier C — Watch / trade-
CabazitaxelTier C — Watch / trade-

Position in synthesis routes (up/downstream chain)

Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.

Paclitaxel/Encequidar mesylateOptimised routesteps: 9total yield: /
Paclitaxel/Encequidar mesylateOptimised routesteps: 4total yield: /
(2alpha,5beta,7beta,10beta,13alpha)-4-(Acetyloxy)-1,7,10,13-tetrahydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate→dichlorodiethylsilane→(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-(acetyloxy)-9-{[diethyl(methoxy)silyl]oxy}-1,12,15-trihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0(3,10).0(4,7)]heptadec-13-en-2-yl benzoate→(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-9-{[diethyl(methoxy)silyl]oxy}-1,15-dihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0(3,10).0(4,7)]heptadec-13-en-2-yl benzoate→(4S,5R)-2,4-Diphenyl-4,5-dihydro-1,3-oxazole-5-carboxylic acid→(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-2-(benzoyloxy)-9-{[diethyl(methoxy)silyl]oxy}-1-hydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0(3,10).0(4,7)]heptadec-13-en-15-yl (4S,5R)-2,4-diphenyl-4,5-dihydro-1,3-oxazole-5-carboxylate

Intermediates available on this site

No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.

This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.